Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Licht

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Current Oncology (Toronto, Ont.)|April 25, 2025
The Role of Dysphagia on Head and Neck Cancer Patients' Quality of Life, Functional Disabilities and Psychological Distress: Outcomes of Cancer Rehabilitation from an Observational Single-Center StudyŠpela Matko, Christina Knauseder, David Riedl, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 28, 2002
Drug selection with paclitaxel restores expression of linked IL-2 receptor gamma -chain and multidrug resistance (MDR1) transgenes in canine bone marrowThomas Licht, Mark Haskins, Paula Henthorn, et al.
British Journal of Haematology|October 14, 2009
Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expressionChristian Bogner, Tobias Dechow, Ingo Ringshausen, et al.
Anti-Cancer Drugs|July 17, 2014
Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding studyMareile Joka, Stefan Boeck, Christoph J Zech, et al.
Oncology|March 9, 2007
Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomasMarcus Schlemmer, Clemens-Martin Wendtner, Martin Falk, et al.
Anti-Cancer Drugs|April 20, 2004
Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR)Klaus Mross, Max E Scheulen, Thomas Licht, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Current Oncology (Toronto, Ont.)|April 25, 2025
The Role of Dysphagia on Head and Neck Cancer Patients' Quality of Life, Functional Disabilities and Psychological Distress: Outcomes of Cancer Rehabilitation from an Observational Single-Center StudyŠpela Matko, Christina Knauseder, David Riedl, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 28, 2002
Drug selection with paclitaxel restores expression of linked IL-2 receptor gamma -chain and multidrug resistance (MDR1) transgenes in canine bone marrowThomas Licht, Mark Haskins, Paula Henthorn, et al.
British Journal of Haematology|October 14, 2009
Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expressionChristian Bogner, Tobias Dechow, Ingo Ringshausen, et al.
Anti-Cancer Drugs|July 17, 2014
Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding studyMareile Joka, Stefan Boeck, Christoph J Zech, et al.
Oncology|March 9, 2007
Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomasMarcus Schlemmer, Clemens-Martin Wendtner, Martin Falk, et al.
Anti-Cancer Drugs|April 20, 2004
Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR)Klaus Mross, Max E Scheulen, Thomas Licht, et al.
Pageof 3